Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Virpax Pharmaceuticals ( (VRPX) ) has shared an announcement.
On February 3, 2025, Jay Panis resigned from Virpax Pharmaceuticals’ Board and its committees due to compliance requirements from his current employer. His departure was not due to disagreements with the company’s operations or policies. Virpax Pharmaceuticals appreciates his contributions and will seek a new independent director to fill the vacancy according to regulatory standards.
More about Virpax Pharmaceuticals
YTD Price Performance: -22.19%
Average Trading Volume: 3,932,137
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $5.34M
See more data about VRPX stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test
- “Direct Result of Your Feedback….” Microsoft Stock (NASDAQ:MSFT) Slips as The Option to Skip Updates Emerges
- Elon Musk’s 2018 Stock Shares Go Live, Tesla Stock (NASDAQ:TSLA) Slips